For a surgeon leaning over an operating table, the view through a traditional optical loupe is fixed. It magnifies, but it cannot annotate, stream, or overlay a patient's MRI scan directly onto the tissue. NuEyes Technologies, a small company operating out of Newport Beach, California, is betting that a digital, augmented reality (AR) loupe can become the new standard. Its devices, which include smart glasses for low-vision patients and AR-enabled digital loupes for clinicians, represent a quiet, hardware-heavy push into regulated medical and assistive technology spaces where the stakes for performance are measured in millimeters of precision and degrees of independence.
Founded in 2016 by U.S. Navy veteran Mark Greget, the company has pursued a path less common in digital health: building its own wearable hardware. While many startups layer software onto commodity devices, NuEyes designs, manufactures, and sells complete systems. Its public traction is modest, with an estimated eight employees and revenue reported under $5 million [RocketReach, 2026]. The company's primary funding to date appears to be a 2021 Regulation Crowdfunding (Reg CF) round that raised just under $107,000 from retail investors via StartEngine, at an estimated $25 million valuation [StartEngine, May 2021]. This capital structure suggests a bootstrap mentality, but the product ambition spans three demanding customer bases.
A hardware wedge in a software world
NuEyes's core thesis is that effective visual augmentation requires purpose-built ergonomics and integrated software. The company's two flagship products illustrate this. The NuLoupes are AR-enabled digital loupes offering 3D stereoscopic vision for surgeons and dentists, designed to replace traditional optical loupes [NuEyes "About Us"]. The Pro 4 smart glasses serve a dual purpose: as a visual aid for individuals with conditions like macular degeneration and glaucoma, and as a heads-up display for medical professionals and enterprise field workers [New England Low Vision, 2026].
This hardware focus creates a tangible, if capital-intensive, moat. The devices are not mere viewers; they are platforms. The NuLoupes, for instance, are intended to allow for graphical overlays, real-time data visualization, and remote collaboration directly in the surgeon's field of view [NuEyes]. For the low-vision market, the Pro 4 glasses connect to a Samsung smartphone, running proprietary NuVision software that can magnify, enhance contrast, and otherwise modify the user's visual feed [Reddit, 2026]. By controlling the full stack, NuEyes aims to solve specific, high-stakes problems where off-the-shelf AR glasses might fall short on comfort, clarity, or clinical utility.
The three-legged market stool
NuEyes is attempting a difficult balancing act by serving three distinct user groups simultaneously. Each represents a different sales motion, regulatory consideration, and value proposition.
| Market Segment | Primary Product | Use Case & Value Proposition |
|---|---|---|
| Medical/Dental Professionals | NuLoupes, Pro 4 | Enhanced surgical precision via 3D AR overlays; ergonomic improvement over traditional loupes [SAGES]. |
| Low-Vision Patients | Pro 4 Smart Glasses | Wearable assistive technology for magnification and contrast enhancement in daily life [Explorium]. |
| Enterprise/Field Workers | Pro 4 Smart Glasses | Hands-free access to manuals, schematics, and remote expert guidance for maintenance and repair [LinkedIn]. |
This diversification could be a strength, spreading risk across revenue streams. The medical and low-vision applications, in particular, share a deep technical lineage in visual enhancement. However, it also demands that a small team master the sales cycles and compliance requirements of both medical device distributors and enterprise procurement departments, a classic challenge for resource-constrained hardware companies.
The regulatory and capital runway
Any device making claims to aid low-vision patients or guide clinical decisions operates in the shadow of the FDA. NuEyes has not publicly disclosed any FDA clearances for its products. For the low-vision glasses, they may be marketed as general wellness or assistive technology, which carries a lower regulatory burden. The NuLoupes, however, if promoted for use in diagnosing conditions or guiding surgical decisions, would likely need to navigate the FDA's 510(k) or De Novo pathways. The company's collaboration with surgeons for design and testing is a positive signal, but peer-reviewed clinical data on outcomes has not been surfaced in public materials [Newswire].
The funding history points to another, more immediate challenge. The 2021 Reg CF round provided a small infusion, but scaling hardware manufacturing, inventory, and a multi-pronged sales effort requires significant capital. The absence of traditional institutional venture investors in the public record suggests the company has, so far, grown through revenue and founder resources. To move from a niche provider to a category-defining player, a larger institutional round may be necessary to fund inventory, expand the commercial team, and potentially pursue regulatory milestones.
Where the focus could fracture
The company's broad market approach introduces credible execution risks. A team of roughly eight people must split its attention across product development, manufacturing, and sales for three different customer archetypes. The competitive landscapes also vary sharply.
- In low-vision assistive tech, NuEyes faces established players like eSight and wearable magnifiers from traditional optics companies. Its wedge is the integration of AR and smartphone connectivity, but it must prove superior utility and comfort to justify a likely premium price.
- In surgical loupes, it competes with giants like Zeiss and Leica, who offer advanced digital visualization systems, as well as a deeply entrenched market for high-quality optical loupes. Convincing surgeons to switch from trusted optical tools to a digital system requires demonstrating unambiguous clinical benefit.
- In enterprise AR, the field is crowded with offerings from Microsoft (HoloLens), Vuzix, and others. Here, NuEyes must compete on price, durability, and software integration in a market often driven by procurement contracts and IT department preferences.
The company's most plausible answer is to double down on its core competency: visual enhancement for high-stakes, precision tasks. By leveraging the same underlying optical and software technology across markets, it can achieve R&D efficiencies. Success in one vertical, particularly the clinically rigorous surgical space, could also serve as a powerful reference case for the others.
The patient in the picture
Ultimately, the most compelling thread in NuEyes's story may be the low-vision application. An estimated 12 million Americans aged 40 and over have vision impairment, including 1 million who are blind and 3 million who have vision impairment after correction [CDC]. Conditions like age-related macular degeneration, diabetic retinopathy, and glaucoma degrade central or peripheral vision, making reading, recognizing faces, and navigating daily life a struggle.
The current standard of care is often a patchwork of low-tech aids: handheld magnifiers, bulky desktop video magnifiers, and screen-reading software. These tools can be effective but are not integrated into a user's natural field of view. They can also be stigmatizing. A wearable device like the Pro 4 glasses aims to be more discreet and functional, offering real-time enhancement of the wearer's entire visual world. The clinical promise is not a cure, but a restoration of functional independence. For a patient with macular degeneration, the ability to read a menu or see a grandchild's face clearly again is the metric that matters far more than the specs of the waveguide inside the glasses.
For NuEyes, the next twelve months will be about proving it can convert its technical prototypes into commercial traction in at least one of its three target markets. A key milestone to watch will be any announced partnership with a medical distributor or a published case study from a hospital system adopting the NuLoupes. Evidence of a larger funding round would signal investor belief that this veteran-founded team can navigate the hard path of regulated hardware and find its foothold in the precise space where human vision needs a digital assist.
Sources
- [RocketReach, 2026] NuEyes Technologies Inc. profile | https://rocketreach.co/nueyes-technologies-inc-profile
- [StartEngine, May 2021] NuEyes StartEngine offering page | https://www.startengine.com/offering/nueyes
- [NuEyes "About Us"] Company about page | https://www.nueyes.com/about-us
- [New England Low Vision, 2026] NuEyes Pro4 Low Vision Glasses overview | https://nelowvision.com/nueyes-pro-4-low-vision-glasses
- [Reddit, 2026] User discussion on Pro 4 functionality | https://www.reddit.com/r/Blind/comments/1d8v8l8/nueyes_pro4_low_vision_glasses
- [SAGES] Society of American Gastrointestinal and Endoscopic Surgeons reference | https://www.sages.org
- [Explorium] Explorium company overview | https://www.explorium.ai/manufacturing/companies/nueyes-technologies
- [LinkedIn] NuEyes Technologies Inc. company profile | https://www.linkedin.com/company/nueyes
- [Newswire] NuEyes press release on surgeon collaboration | https://www.accesswire.com
- [Forbes, 2023] Article on NuEyes optical loupe prototype | https://www.forbes.com/sites/jenniferhicks/2023/04/28/this-new-optical-loupe-prototype-has-an-augmented-reality-overlay
- [CDC] Vision Impairment and Blindness data | https://www.cdc.gov/visionhealth/basics/ced/fastfacts.htm